Multiple lines of chemotherapy for patients with high‐grade ovarian cancer: Predictors for response and effect on survival-Reference-Cited by-同舟云学术

Multiple lines of chemotherapy for patients with high‐grade ovarian cancer: Predictors for response and effect on survival

Published:2020-12-07 Issue:9 Volume:148 Page:2304-2312
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Kessous Roy¹^ORCID,Wissing Michel D.²,Laskov Ido¹,Abitbol Jeremie¹,Bitharas Joanna¹,Agnihotram Venkata R.²,Yasmeen Amber¹,Salvador Shannon¹,Lau Susie¹,Gotlieb Walter H.¹

Affiliation:

1. Division of Gynecologic Oncology, Segal Cancer Center, Lady Davis Institute of Research, Jewish General Hospital McGill University Quebec Canada

2. Division of Cancer Epidemiology, Gerald Bronfman Department of Oncology McGill University Quebec Canada

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33395

Reference19 articles.

1. Why have ovarian cancer mortality rates declined? Part I. Incidence

2. Cancer statistics, 2015

3. Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership

4. Ovarian Cancer, Version 3.2012

5. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses;BJC Reports;2024-06-20

2. Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial;International Journal of Gynecologic Cancer;2024-06-10

3. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum- resistant or refractory ovarian / fallopian tube / primary peritoneal cancer (NCT03093155): updated survival and subgroup analyses;2024-05-21

4. Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO);Cancers;2024-03-14

5. Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers;Cancer Medicine;2023-12-22